| Name | Title | Contact Details |
|---|
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
For more than 235 years, Takeda has been serving society with innovative medicines, helping patients reclaim valuable moments of life from illness. Now, with new healthcare solutions from prevention to care and cure, we are determined to help even more people enjoy their lives to the fullest. Our mission is simple: we strive toward better health for patients worldwide through leading innovation in medicine. This mission: • Drives our research and development of prescription drugs • Promotes our commitment to social responsibility • Marks our growth and success At Takeda, our passion for healthcare and commitment to improving lives will enable us to make the next 230 years healthier and brighter for people around the world. Our robust product pipeline is focused on treating serious diseases and disorders, including bone and joint disorders, cardiovascular disease, central nervous system disorders, chronic kidney disease, diabetes, gastroenterology, gynecological disorders and infectious disease.
Orascoptic offers award-winning, custom-fit dental and surgical loupes and headlights for loupes with a 45-day trial period.
SCA Pharma is a leading FDA 503B outsourcing facility delivering the highest quality sterile admixtures and pre-filled syringes to hospitals and health systems nationwide. SCA Pharma prides itself on being the most customer- and patient-focused 503B in the industry. Known for its unwavering quality and high-touch customer service, SCA Pharma is headquartered in Little Rock, AR with a sister facility in Windsor, CT. The Windsor facility boasts more than 90,000 square feet of sterile compounding laboratory and manufacturing space while Little Rock is home to SCA Pharma`s 17,000 square foot sterile compounding facility. Both facilities meet or exceed FDA cGMP manufacturing guidelines. SCA Pharma employs more than 500 people across both facilities, as well as a team of sales representatives across the country.
Nautilus Biosciences Canada is a Charlottetown, PE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.